

Resource Summary Report

Generated by [RRID](#) on Sep 10, 2026

Oncotest

RRID:SCR_000489

Type: Tool

Proper Citation

Oncotest (RRID:SCR_000489)

Resource Information

URL: <http://www.oncotest.com/>

Proper Citation: Oncotest (RRID:SCR_000489)

Description: A contract research organization (CRO) specializing in preclinical oncology services. As a pioneer in the field of patient derived tumor xenografts (PDX), they provide tailored solutions to the problems faced by preclinical oncology researchers. They assist with the identification of the best drug candidates and the validation of their targets and deliver in-depth bioinformatics analyses, laying the groundwork for the successful planning of clinical trials. Their diverse tumor model collection enables them to recommend the right assays and models to answer their customers' questions. Their AAALAC accredited facilities with IVC system, separate model development unit, large cage capacity of over 14,500 mice and proprietary electronic measurement system with an integrated database and by continuously maintaining important PDX models in mice, they are able to provide the highest standard of testing within a reasonable timeframe.

Abbreviations: Oncotest

Synonyms: Oncotest GmbH

Resource Type: commercial organization

Keywords: preclinical, oncology, xenograft

Related Condition: Cancer, Tumor

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Resource Name: Oncotest

Resource ID: SCR_000489

Alternate IDs: nlx_158264

Record Creation Time: 20220129T080201+0000

Record Last Update: 20260905T132420+0000

Ratings and Alerts

No rating or validation information has been found for Oncotest.

No alerts have been found for Oncotest.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Savoca A, et al. (2026) Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors. Molecular cancer therapeutics, 25(7), 1157.

Vuaroqueaux V, et al. (2023) High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models. Cancer research communications, 3(10), 2170.